Lab Manager | Run Your Lab Like a Business

Nuclera Acquires E Ink Digital Microfluidics Unit

Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience

by
Nuclera

Nuclera is the leading pioneer in making biology accessible through desktop enzymatic protein and gene synthesis. Headquartered in Cambridge, UK, Nuclera was founded in 2013 by four PhD students at...

ViewFull Profile.
Learn about ourEditorial Policies.
Register for free to listen to this article
Listen with Speechify
0:00
5:00

CAMBRIDGE, UK; BILLERICA, MA — May 12th, 2021 — Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance.  

Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in conventional microfluidics, digital microfluidics uses electronic signals to guide microdroplets. When combined with Nuclera biopolymer synthesis, this advanced lab-on-a-chip technology will enable a user to digitally program the next day bioprinting of proteins and genes on a desktop device.  The result is a bioprinter that gives unprecedented access to biology. Commercialization is expected in 2022. 

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

In the transaction, E Ink will contribute intellectual property, equipment, and highly specialized scientists and engineers. Reciprocally, E Ink will become the largest strategic shareholder in Nuclera. The resulting Nuclera US subsidiary will be co-located within the E Ink Innovation Center in Billerica MA, a short distance from the growing biotech technology hub in Cambridge MA. The combination of these two efforts into one company will further increase the rate of development, commercialization, and adoption of this ground-breaking product as well as consolidate the intellectual property position. E Ink will continue to be a strategic supplier to Nuclera for key electronic components of Nuclera’s desktop bioprinter. 

Dr. Michael Chen, co-founder and CEO of Nuclera, commented: “Our partner, E Ink, made reading accessible by printing words with electronic ink. We are proud to work with E Ink to make biology accessible by printing biology with digital microfluidics. This acquisition allows Nuclera to combine the biological with the digital in one product and under one roof. We now look forward to further strengthening our strategic partnership with E Ink through joint R&D, manufacturing, and product development projects.”

Dr. Michael McCreary, chief innovation officer of E Ink said: “This spinout and ongoing relationship with Nuclera gives E Ink the opportunity to leverage our knowledge and capabilities in electronic paper technology into the growing biotechnology sector which has increasingly critical importance to the current and future challenges in global health and sustainability.  We are pleased to be able participate in this market through an equity stake in Nuclera and look forward to the continuing relationship as a strategic supplier to and equity partner with Nuclera.”

For more information, about Nuclera, visit https://www.nuclera.com